(Q37801988)

23 August 2017

title

Where to position clozapine: re-examining the evidence (English)

1 reference

23 August 2017

Where to Position Clozapine: Re-Examining the Evidence (English)

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

7 August 2024

4

Gary Remington

1 reference

23 August 2017

1

Ofer Agid

1 reference

23 August 2017

2

George Foussias

1 reference

23 August 2017

Shayna Singh

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

Canadian Journal of Psychiatry

23 August 2017

published in

1 reference

23 August 2017

volume

55

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

677-684

1 reference

The history of clozapine and its emergence in the US market: a review and analysis

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

21 January 2018

The history of clozapine

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Dopamine receptors and the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Evidence-based pharmacotherapy of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

The 'atypicality' of antipsychotics: a concept re-examined and re-defined

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Augmentation strategies in clozapine-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Therapeutic effects of clozapine. A 4-year follow-up of a controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Update on the clinical efficacy and side effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Evaluation of treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Results of phase 3 of the CATIE schizophrenia trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

CLOZAPINE AND AGRANULOCYTOSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Mortality in current and former users of clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Two cases of olanzapine-induced reversible neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Olanzapine-induced agranulocytosis: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Early use of clozapine for poorly responding first-episode psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Cost of relapse in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Suicidal risk during treatment with clozapine: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

EPS profiles: the atypical antipsychotics are not all the same

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

The emerging role of clozapine in the treatment of movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Cardiac side effects of psychiatric drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

What CATIE found: results from the schizophrenia trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

The cost-effectiveness of clozapine: a survey of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Predictors of long-term outcome in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Predictors and markers of clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Artificial neural network prediction of clozapine response with combined pharmacogenetic and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Genetic predictors of therapeutic response to clozapine: current status of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Clozapine-induced agranulocytosis and its genetic determinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005501007

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

Second-generation antipsychotics: discrepancies between licensed indications, evidence base and actual use

7 August 2024

7

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

Journal of Psychiatry & Neuroscience

7 August 2024

8

28

275

Remington G.

2003

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

Hospital & community psychiatry

7 August 2024

34

40

1310

No authors listed

1989

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland

7 August 2024

39

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

Haematological safety of antipsychotic drugs

7 August 2024

44

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

Treating movement disorders and akathisia as side effects of antipsychotic pharmacotherapy

7 August 2024

48

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

7 August 2024

50

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

Effectiveness of switching antipsychotic medications

7 August 2024

51

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

Are antipsychotic drugs interchangeable?

7 August 2024

52

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

Tardive dyskinesia circa 2006

7 August 2024

65

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

7 August 2024

75

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

7 August 2024

77

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine.

7 August 2024

80

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

Is early intervention in psychosis effective?

7 August 2024

83

1 reference

https://api.crossref.org/works/10.1177/070674371005501007

7 August 2024

Identifiers

1 reference

23 August 2017

1 reference